ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0131

Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies After SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study

Carol Hitchon1, Dawn Bowdish2, Gilles Boire3, Paul Fortin4, Louis Flamand5, Vinod Chandran6, Roya M Dayam7, Anne-Claude Gingras8, Catherine Card9, Ines Colmegna10, Maggie Larche2, Gil Kaplan11, Luck Lukusa12, Jennifer Lee12 and Sasha Bernatsky13, and SUCCEED investigative team, 1University of Manitoba, Winnipeg, MB, Canada, 2McMaster University, Hamilton, ON, Canada, 3Retired, Sherbrooke, QC, Canada, 4Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 5Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, 6University of Toronto, Toronto, ON, Canada, 7Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada, 8Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada, 9National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada, 10The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 11University of Calgary, Calgary, AB, Canada, 12The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 13Research Institute of the McGill University Health Centre, Montreal, QC, Canada

Meeting: ACR Convergence 2024

Keywords: Anti-TNF Drugs, COVID-19, Disease-Modifying Antirheumatic Drugs (Dmards), Miscellaneous Rheumatic and Inflammatory Diseases, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Epidemiology & Public Health Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Given ongoing SARS-CoV-2 circulation, COVID-19 vaccination response in immune-mediated inflammatory disease (IMID) remains a key issue, particularly regarding effects of common immunosuppressives like methotrexate and tumor necrosis factor inhibitors (TNFi). To date, studies focussed on a single disease and/or a single centre, or assessed only ancestral strains and/or only the presence of antibodies and not viral neutralization ability.  When combining data across centres to achieve a larger and diverse sample, sophisticated modeling must allow for differences across centres, while aiming to achieve a single estimate of effects. Our purpose was to overcome these challenges.

Methods: Prospectively collected data and sera on adults with inflammatory bowel disease (IBD), rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) were collected at academic centres in Alberta, Manitoba, Ontario, and Quebec. Five labs were used, all performed neutralization for the ancestral strain, four labs also assessed omicron BA1, and three assessed ancestral BA5. Two serum samples from each participant, collected between 2022-2023, were assessed. Each lab’s results were analyzed separately using multivariate generalized logit models (with ordinal outcomes for no, low, medium, and high neutralization ability) and then pooled in random-effects meta-analyses for ancestral, BA1 and BA5 strains.

Results: We studied 479 individuals; 292 (61%) were IBD, 141 (29.4%) RA, 24 PsA (5%), 13 SpA (2.7%) and 9 SLE (1.9%). Most (n=447, 93.3%) individuals were white, 62.2 % were female, and the mean age was 56.8 (standard deviation 14.8) years. Other characteristics are shown in Table 1. Table 2 shows the ORs, adjusted for sex, age, race/ethnicity, IMID, DMARD, biologics, prednisone, and details of past COVID vaccinations and infections. For both individual labs and the meta-analyses, adjusted ORs suggested that TNFi and methotrexate were independently associated with less neutralization ability.

Conclusion: Neutralization responses in immunosuppressed IMID hosts may be diminished by both TNFi and methotrexate in an independent manner.  

Supporting image 1

Table 1: Description of SUCCEED participants

Supporting image 2

Table 2. Multivariate ordered logit regressiona and random-effects meta-analysesb: Adjusted odds ratios (aOR) for methotrexate and tumor-necrosis factor inhibitors (TNFi) effects.


Disclosures: C. Hitchon: None; D. Bowdish: AstraZeneca, 1, Federal Government, 6, Pfizer, 1; G. Boire: AbbVie/Abbott, 1, Biocon, 5, Orimed, 2, 6, Otsuka, 1, Pfizer, 5, Sanofi, 1; P. Fortin: AstraZeneca, 2, 6, GlaxoSmithKlein(GSK), 2, 6, Moderna, 2; L. Flamand: None; V. Chandran: AbbVie/Abbott, 1, 5, AstraZeneca, 12, Spousal employment, Bristol-Myers Squibb(BMS), 1, Eli Lilly, 1, Janssen, 1, Novartis, 1, UCB, 1; R. Dayam: None; A. Gingras: None; C. Card: None; I. Colmegna: None; M. Larche: None; G. Kaplan: AbbVie/Abbott, 6, Ferring, 5, Janssen, 6, Pfizer, 6, Takeda, 2, 6; L. Lukusa: None; J. Lee: None; S. Bernatsky: None.

To cite this abstract in AMA style:

Hitchon C, Bowdish D, Boire G, Fortin P, Flamand L, Chandran V, Dayam R, Gingras A, Card C, Colmegna I, Larche M, Kaplan G, Lukusa L, Lee J, Bernatsky S. Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies After SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/methotrexate-and-tumor-necrosis-factor-inhibitors-independently-decrease-neutralizing-antibodies-after-sars-cov-2-vaccination-updated-results-from-the-succeed-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/methotrexate-and-tumor-necrosis-factor-inhibitors-independently-decrease-neutralizing-antibodies-after-sars-cov-2-vaccination-updated-results-from-the-succeed-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology